Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Change in Accured Expenses (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Change in Accured Expenses for 4 consecutive years, with $445639.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 828.12% to $445639.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $785379.0, a 1285.71% increase, with the full-year FY2024 number at $501412.0, up 333.5% from a year prior.
  • Change in Accured Expenses was $445639.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$252166.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $461456.0 in Q4 2022 to a low of -$399653.0 in Q3 2023.
  • A 4-year average of $77811.2 and a median of $77038.0 in 2023 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 1026.81% in 2025; the steepest drop was 351.78% in 2025.
  • 60 Degrees Pharmaceuticals' Change in Accured Expenses stood at $461456.0 in 2022, then tumbled by 124.86% to -$114734.0 in 2023, then soared by 387.62% to $330001.0 in 2024, then surged by 35.04% to $445639.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Change in Accured Expenses are $445639.0 (Q3 2025), -$252166.0 (Q2 2025), and $261905.0 (Q1 2025).